DCI Partners logo

DCI Partners

Asia, Tokyo, Japan, Tokyo

Description

DCI Partners is a venture capital firm specializing in the fields of drug discovery and regenerative medicine.

Investor Profile

DCI Partners has made 4 investments, with 3 in the past 12 months and 50% as lead.

Stage Focus

  • Series B (50%)
  • Series C (25%)
  • Series A (25%)

Country Focus

  • Japan (75%)
  • United States (25%)

Industry Focus

  • Biotechnology
  • Health Care
  • Manufacturing
  • Medical
  • Rental
  • Pharmaceutical
  • Product Research
  • Health Diagnostics
  • Life Science
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does DCI Partners frequently co-invest with?

Co-Investments: 1
Global Brain Corporation
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
Asahi Kasei
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
QB Capital
Asia, Fukuoka, Japan, Fukuoka
Co-Investments: 2
CV
Asia, Kyoto, Japan, Kyoto
Co-Investments: 1
JAFCO
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
Tohoku University Venture Partners
Asia, Miyagi, Japan, Sendai-shi
Co-Investments: 2
JIC Venture Growth Investments
Asia, Tokyo, Japan, Marunouchi
Co-Investments: 1
Golden Asia Fund Venture
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
Nippon Venture Capital
Asia, Tokyo, Japan, Tokyo
Co-Investments: 2

What are some of recent deals done by DCI Partners?

Apeximmune Therapeutics

Burlingame, California, United States

Apeximmune Therapeutics engages in the discovery and development of novel biologics that modulate the immune system.

BiotechnologyHealth DiagnosticsLife Science
Series AMar 31, 2025
Amount Raised: $21,300,000
Rege Nephro

Kyoto, Kyoto, Japan

Rege Nephro is a biotech company that specializes in R&D, production, and marketing of renal disease therapeutics.

BiotechnologyManufacturingMedicalRental
Series BOct 7, 2024
Amount Raised: $15,189,217
Luxna Biotech

Osaka, Osaka, Japan

Luxana Biotech is established to contribute to medical treatment for suffering patients, .

BiotechnologyHealth CareProduct Research
Series CSep 6, 2024
Amount Raised: $1,686,282
LUCA Science

Tokyo, Tokyo, Japan

LUCA Science develops innovative treatments intended for mitochondrial and related diseases.

BiotechnologyHealth CarePharmaceutical
Series BJun 6, 2022
Amount Raised: $29,203,600